news
Unlocking the Next Generation of Biomarkers: Introducing TAmiRNA’s New circRNA Analysis ServiceUnlocking the Next Generation of Biomarkers: Introducing TAmiRNA’s New circRNA Analysis Service
biomarker, Biomarker Discovery, biomarkers, circRNA analysis service, liquid biopsies, microRNAs, NGS, small RNA-sequencing
Unlocking the Next Generation of Biomarkers: Introducing TAmiRNA’s New circRNA Analysis Service
The world of non-coding RNAs is continually expanding, revealing new layers of biological complexity and therapeutic potential. Among the most exciting discoveries are circular RNAs (circRNAs). Unlike their linear counterparts, circRNAs form covalently closed loops, granting them remarkable stability and unique functions in gene regulation. This intrinsic stability, coupled with their presence in biofluids, positions circRNAs as powerful new candidates for biomarker discovery [...]
Transcriptomics Webinar Announcement
🔬 Join us for an insightful transcriptomics webinar where we will delve into cutting-edge strategies for biomarker discovery, basic research, and translational applications. Whether you're focused on diagnostics or overcoming the challenges of low-input sample analysis, this webinar is designed for you! Title: Harnessing Transcriptomics: microRNA and mRNA analysis for Biomarker Discovery, Basic Research, and Translational Applications What to Expect: Comprehensive Transcriptomics Sequencing Services [...]
EVscale™ and TAmiRNA at ISEV Vienna, April 24-27, 2025
We are thrilled to announce that TAmiRNA, Evercyte, and Phoenestra have united to form EVscale™, a powerful collaboration dedicated to providing comprehensive solutions for extracellular vesicle (EV) research, diagnostic, and therapeutic development. We will be exhibiting at the prestigious ISEV (International Society for Extracellular Vesicles) Conference in Vienna from April 24-27, 2025, and we invite you to visit us at Booth B13. The [...]
TAmiRNA and Medical University of Vienna Advance Liver Surgery Safety with hepatomiR®
TAmiRNA has joined forces with the Medical University of Vienna to develop an innovative microRNA test (hepatomiR®) to improve safety in liver surgery. The pioneering qPCR-based test is founded on original research by two of the university’s associate professors, Dr. Alice Assinger, Head of the Vienna Platelet Lab, and Dr. Patrick Starlinger, who heads the university’s TELL Translational and Experimental Liver Laboratory. Their [...]
7Bioscience and TAmiRNA collaborate to expand access to our cutting-edge transcriptomics services
We are delighted to welcome 7Bioscience as the new distribution partner of TAmiRNA GmbH! With a strong track record in clinical and research molecular biology, 7Bioscience will support to offer TAmiRNA’s innovative service solutions to a broader audience. This partnership will enhance accessibility to our cutting-edge transcriptomics analysis. We look forward to a successful collaboration with 7Bioscience and the opportunities this partnership will [...]
TAmiRNA ‘2024 In Review’TAmiRNA ‘2024 In Review’
biomarker, Biomarker Discovery, biomarkers, CE-IVD, congress, EVscale, exosomes, extracellular vesicle, hepatomiR kit, Illumina NewSeq2000, ISO 13485, liquid biopsies, Liver disease, microRNA, microRNA services, microRNAs, NGS, PCR testing service, quality, sequencing, small RNA-sequencing, smallRNA, test service
TAmiRNA ‘2024 In Review’
2024: A Year of Growth, Innovation, and Collaboration 2024 has come to a close. We are proud to reflect on the milestones and achievements we’ve reached together with our incredible team, customers, partners, and supporters. Here’s a look back at what we accomplished this year: 👩🔬 Team Expansion Welcomed 3 talented new members to our growing team. 🏥 Diagnostic Implementation Successfully rolled out our [...]
TAmiRNA at SURGER-I Innsbruck Congress 2024
We are thrilled to announce that TAmiRNA will participate in the SURGER-I Innsbruck Congress on December 12–13, 2024. This premier event brings together leading experts, researchers, and practitioners to explore advancements in hepatopancreatobiliary surgery and transplantation. As a proud sponsor, we will showcase our hepatomiR® kit, the first CE-IVD microRNA biomarker for the pre-operative assessment of liver function. Attendees can find us featured [...]
Webinar Announcement
🔬 Join us for an insightful webinar on transcriptomics where we will delve into cutting-edge strategies for biomarker discovery, basic research, and translational applications. Whether you're focused on diagnostics or overcoming the challenges of low-input sample analysis, this webinar is designed for you! Title: Harnessing Transcriptomics: microRNA and mRNA analysis for Biomarker Discovery, Basic Research, and Translational Applications What to Expect: Comprehensive Transcriptomics [...]
TAmiRNA at Precision EV Forum in Cambridge
Excited to share that TAmiRNA and Evercyte will join forces at the upcoming Precision EV Forum in Cambridge! 🚀 As key members of the EVscale® consortium, they’ll be showcasing cutting-edge solutions in EV (extracellular vesicles) characterization and therapeutics. TAmiRNA will present its advanced multiomic capabilities for RNA cargo characterization, aiding in biomarker discovery. Evercyte will highlight its clinical-grade EVs produced from telomerized MSCs, [...]
Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitusEager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus
biomarker, bone diseases, bone fracture risk assessment, diabetes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA
Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus
Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of [...]